The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

被引：103

作者：

Wang, Xueping ^{[1
]}

Wang, Fang ^{[1
]}

Zhong, Mengjun ^{[1
]}

Yarden, Yosef ^{[2
]}

Fu, Liwu ^{[1
]}

机构：

[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangdong Esophageal Canc Inst,Canc Ctr, Guangzhou, Peoples R China

[2] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel

来源：

MOLECULAR CANCER | 2020年 / 19卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Immunotherapy; PD-1; PD-L1; Hyperprogressive disease; Biomarker; REGULATORY T-CELLS; ADVANCED MELANOMA; SUPPRESSOR-CELLS; LUNG-CANCER; RESPONSE CRITERIA; PD-1; BLOCKADE; MYELOID CELLS; STAGE IV; IMMUNOTHERAPY; NIVOLUMAB;

D O I：

10.1186/s12943-020-01200-x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers. However, low response rates to ICI monotherapies and even hyperprogressive disease (HPD) have limited the clinical application of ICIs. HPD is a novel pattern of progression, with an unexpected and fast progression in tumor volume and rate, poor survival of patients and early fatality. Considering the limitations of ICI due to HPD incidence, valid biomarkers are urgently needed to predict the occurrence of HPD and the efficacy of ICI. Here, we reviewed and summarized the known biomarkers of HPD, including tumor cell biomarkers, tumor microenvironment biomarkers, laboratory biomarkers and clinical indicators, which provide a potential effective approach for selecting patients sensitive to ICI cancer treatments.

引用

页数：15

共 87 条

[1] SnapShot: Immune Checkpoint Inhibitors [J].

Abril-Rodriguez, Gabriel ;

Ribas, Antoni .

CANCER CELL, 2017, 31 (06)

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy [J].

Alexander, Gregory S. ;

Palmer, Joshua D. ;

Tuluc, Madalina ;

Lin, Jianqing ;

Dicker, Adam P. ;

Bar-Ad, Voichita ;

Harshyne, Larry A. ;

Louie, Jennifer ;

Shaw, Colette M. ;

Hooper, D. Craig ;

Lu, Bo .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[4] Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types [J].

Ascierto, Paolo A. ;

Kalos, Michael ;

Schaer, David A. ;

Callahan, Margaret K. ;

Wolchok, Jedd D. .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1009-1020

[5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[6] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[7] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[8] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

[9] Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation [J].

Cheng, J-t ;

Deng, Y-n ;

Yi, H-m ;

Wang, G-y ;

Fu, B-s ;

Chen, W-j ;

Liu, W. ;

Tai, Y. ;

Peng, Y-w ;

Zhang, Q. .

ONCOGENESIS, 2016, 5 :e198-e198

[10] Cancer-associated fibroblasts induce PDL1+neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma [J].

Cheng, Yusheng ;

Li, Hui ;

Deng, Yinan ;

Tai, Yan ;

Zeng, Kaining ;

Zhang, Yingcai ;

Liu, Wei ;

Zhang, Qi ;

Yang, Yang .

CELL DEATH & DISEASE, 2018, 9

← 1 2 3 4 5 6 7 8 9 →